



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/583,003	06/13/2006	Edson Begliomini	13779-69	6373
45473 7590 11/24/2010 BRINKS, HOFER, GILSON & LIONE P.O. BOX 110285 RESEARCH TRIANGLE PARK, NC 27709				
EXAMINER				
LEVY, NEIL S				
ART UNIT		PAPER NUMBER		
1615				
MAIL DATE		DELIVERY MODE		
11/24/2010		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/583,003

Applicant(s)

BEGLIOMINI ET AL.

Examiner

NEIL LEVY

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 14 September 2010.
2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 15-41 is/are pending in the application.
4a) Of the above claim(s) 41 is/are withdrawn from consideration.
5) ☐ Claim(s) _____ is/are allowed.
6) ☒ Claim(s) 15-40 is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☒ Claim(s) 15-41 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO/SI.08)
4) ☐ Interview Summary (PTO-413)
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____
Paper No(s)/Mail Date 9/14/2010

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim 41 IS withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 4/20/2010

The 112 rejection is withdrawn, in view of amendment.

Claim Rejections - 35 USC § 103

Claims 15-17, 20, 22-40 stand rejected under 35 U.S.C. 103(a) as being unpatentable over MULLER et al 5869517 and BUNTAIN et al EPO295117.

At MULLER see Formula 1.1, Table 5,(column 18) the instant Formula I, when one line at Table A is a halogen; numbers 2-5, 8-17 for example, at column 21, meet the instant I. These compounds control fungi, insects, arachnids and nematodes (col 28, lines 48-50). Actives are 0.0001 to 95%, with carriers of liquid or solid (col 33). Application is to fungi, seed, plants or soil (col 34, lines 20-45) at 0.02-3kg/ha, with other pesticides at a ratio of 1:10 to 10:1.
Insect species includes heliothis virescens (col 28, line 67).

The instant Formula II is not specified. BUNTAIN at compounds 52,57,58,59 are the instant Formula II, effective for nematode, arachnid and insect control such as *heliiothis virescens* (page 5, lines 6, 7). Application is in liquid or solid carrier (page 5, lines 50-61) to plants, soil, and seed. Application rates is 0.00001-95% (page 8, lines 6-10) with other pesticides.

Both formulae control insects such as *heliiothis* species, and thus it would be obvious to combine them using the same carriers at the ratio taught by MULLER of 1:10 to 10:1, in order to enhance efficacy of control. Further, the composition as such would also control fungi, thus providing the added benefit of dual pest control with one application.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made desiring to utilize pest control means, to use any of art recognized means, as of MULLER and BUNTAIN modified as desired to increase stability, dispersibility, compatability of ingredients, processing ease, & toxicity.

All the critical elements of the instant are disclosed. The amounts and proportions of each ingredient are result effective parameters chosen to obtain the desired effects. It would be obvious to vary the form of each ingredient to optimize the effect desired, depending upon the particular species and application method of interest, reduction of toxicity, cost minimization, enhanced, and prolonged, or synergistic effects.

Applicant has not provided any objective evidence of criticality, nonobvious or unexpected results that the administration of the particular ingredients' except for double the amounts of Fipronil & pyraclostrobin applied to rice to kill green leafhopper provides any greater or different level of prior art expectation as claimed, and the use of ingredient for the functionality for which they are known to be used is not basis for patentability.

The instant invention provides well known old art recognized compounds, with well known art recognized effects, applied by well known art recognized methods to achieve improved control as is well known in the art.

Claims 15-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over MULLER et al 5869517 and BUNTAIN et al EPO295117 as applied to claims 15 above, and further in view of BROWN et al 5747516

The instant compositions and methods are obvious over BUNTAIN AND MULLER (above) but the claimed added fungicide was not presented. BROWN shows the advantage of added fungicides, of the instant claim 19 thiophanat—methyl, the elected species (col. 61, top) with instant Formula II fipronil (col. 60, lines 49). One could in one application, apply fungicide & insecticide with a mix of fungicides providing a wider spectrum of action and control of resistant fungi (col. 61, lines 12-15). Application is as in MULLER and BUNTAIN (col. 61, lines 16-30) at the instant rates.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made desiring to control fungus & insects of crops, to use MULLER and BUNTAIN modified with additional antifungal actives in order to protect against resistant fungi.

Double Patenting

Claim 15-18, 22, 23, 26, 29, 32, 35, 38 STAND provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 35-37, 40, 41 of copending Application No. 121524137 as US 2010/0105669. Although the conflicting claims are not identical, they are not patentably distinct from each other because The instant claims are anticipated by 121524137.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir.

1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Applicant's arguments filed 9/14/10 have been fully considered but they are not persuasive. Applicant's arguments for synergy are not persuasive; the declaration is beyond the scope of the claims. The declaration is a method, applying 500 +500 ppm of Fipronil & pyraclostrobin to rice to kill leafhoppers, while the claims are to over 100 variants of fipronil with 384 variants of . pyraclostrobin, or 38,400 possible mixes. Applicant sees 57000 mixes with Muller & Buntain,; not an order of magnitude different; both cases taxing testing , but not formative or conceptual work.

As to Brown, here it is cited to show known fungicides with insecticides.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL LEVY whose telephone number is 571-272-0619. The examiner can normally be reached on Tuesday-Friday, 7 AM to 5:30 PM EST..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, ROBERT A. WAX can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/NEIL LEVY/
ART UNIT 1615

11/20/2010